Dialybrid
Silkothane hybrid arteriovenous grafts for hemodialysis access
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Dialybrid S.r.l. is a clinical-stage medical device company in Cantù, Italy, developing arteriovenous vascular grafts for hemodialysis based on Silkothane®, a patented hybrid material of silk fibroin and polyurethane. Its lead product, the Silkothane® Arteriovenous Graft, is engineered for faster cannulation and durability versus conventional access options. In September 2026 the company announced a €15 million Series A led by XGEN Venture with participation from CDP Venture Capital (Rilancio Fund), alongside the first-in-human implant in an Italian pilot trial. Public site: dialybrid.com.
- Website
- dialybrid.com
- Stage
- series-a
- Founded
- 2020
- Location
- Cantù, Italy
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Silkothane Arteriovenous Graft — Hybrid silk fibroin–polyurethane graft for hemodialysis access